In Re Genentech, Inc.

566 F.3d 1338, 91 U.S.P.Q. 2d (BNA) 1027, 2009 U.S. App. LEXIS 10882
CourtCourt of Appeals for the Federal Circuit
DecidedMay 22, 2009
Docket2009-M901
StatusPublished

This text of 566 F.3d 1338 (In Re Genentech, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Genentech, Inc., 566 F.3d 1338, 91 U.S.P.Q. 2d (BNA) 1027, 2009 U.S. App. LEXIS 10882 (Fed. Cir. 2009).

Opinion

ORDER

LINN, Circuit Judge.

Genentech, Inc. (“Genentech”) and Biog-en Idee Inc. (“Biogen”) petition for a writ of mandamus to direct the United States District Court for the Eastern District of Texas to vacate its March 19, 2009 order denying the petitioners’ motion to transfer venue, and to direct that court to transfer the case to the United States District Court for the Northern District of California. Sanofi-Aventis Deutschland GmbH (“Sanofi”) opposes. The petitioners move for leave to reply.

I. BACKGROUND

Genentech, which is headquartered in San Francisco, California, and Biogen, which has facilities in San Diego, California, are defendants in a patent infringement suit brought by the German company, Sanofi. Sanofi brought the suit in the District Court for the Eastern District of Texas, a venue which indisputably has no *1341 connection to any of the witnesses or evidence relevant to the cause of action. On the same day, the petitioners filed a related declaratory judgment action in the Northern District of California, seeking a declaration of invalidity and noninfringement of Sanofi’s patents.

The petitioners filed a motion pursuant to 28 U.S.C. § 1404(a) to transfer the Texas case to the Northern District of California. The petitioners argued that at least ten potential material witnesses, including two of the patent prosecution attorneys, reside in the Northern District, and at least four additional potential witnesses are residents of California. The petitioners further argued that all of their documents relating to the development and marketing of the accused infringing products were either in the proposed transferee jurisdiction or in San Diego, California.

Sanofi opposed transfer, contending that the Eastern District of Texas was the proper venue. Sanofi argued that the Eastern District of Texas was centrally located between the parties and would be more convenient for the six inventors who reside in Europe, a prior art author who resides in Iowa who could be a potential witness, and the remaining four prosecuting patent attorneys who reside on the U.S. East Coast. Sanofi also argued that a denial of transfer could prevent a waste of judicial resources by avoiding the need for the Northern District of California to decide whether it had personal jurisdiction over Sanofi with regard to the petitioners’ declaratory judgment action.

On March 19, 2009, the Eastern District of Texas denied petitioners’ request to transfer. Regarding the convenience of the witnesses, the court noted that although several witnesses resided in the Northern District of California, none were identified by the petitioners as “key witnesses.” The court also emphasized Texas’s central physical location to the foreign and U.S. witnesses and parties. Finally, the court stated that the Northern District of California’s possible lack of personal jurisdiction over Sanofi, and Genentech’s previous appearance as a plaintiff in the Eastern District of Texas, counted significantly against transfer. The petitioners ask us for a writ of mandamus directing the Eastern District of Texas to vacate its order and transfer the case pursuant to 28 U.S.C. § 1404(a).

II. DISCUSSION

The writ of mandamus is available in extraordinary situations to correct a clear abuse of discretion or usurpation of judicial power. In re Calmar, Inc., 854 F.2d 461, 464 (Fed.Cir.1998). A party seeking a writ bears the burden of proving that it has no other means of obtaining the relief desired, Mallard v. U.S. Dist. Court for S. Dist. of Iowa, 490 U.S. 296, 309, 109 S.Ct. 1814, 104 L.Ed.2d 318 (1989), and that the right to issuance of the writ is “clear and indisputable,” Allied Chem. Corp. v. Daiflon, Inc., 449 U.S. 33, 35, 101 S.Ct. 188, 66 L.Ed.2d 193 (1980). The use of mandamus to correct a patently erroneous denial of transfer pursuant to § 1404(a) has been approved under the rulings of the Fifth Circuit in appropriate circumstances. See In re TS Tech USA Corp., 551 F.3d 1315, 1319 (Fed.Cir.2008) (issuing mandamus to transfer patent case out of the Eastern District of Texas where all identified witnesses and evidence were located in alternative venue); In re Volkswagen of Am., Inc., 545 F.3d 304 (5th Cir.2008) (en banc) (same).

A. Transfer of Venue Pursuant to 28 U.S.C. § 1404(a)

The basic principles governing transfer of venue under the law of the Fifth Circuit are well settled and are not in dispute here. Pursuant to § 1404(a), “[f]or the convenience of parties and witnesses, in the interest of justice, a district *1342 court may transfer any civil action to another district court or division where it might have been brought.” 28 U.S.C. § 1404(a). A motion to transfer venue should be granted upon a showing that the transferee venue “is clearly more convenient” than the venue chosen by the plaintiff. Volkswagen, 545 F.3d at 315.

In assessing whether a defendant has met its burden of demonstrating the need to transfer, the Fifth Circuit applies the “public” and “private” factors for determining forum non conveniens. Volkswagen, 545 F.3d at 314 n. 9. As we noted in TS Tech, the private interest factors include “(1) the relative ease of access to sources of proof; (2) the availability of compulsory process to secure the attendance of witnesses; (3) the cost of attendance for willing witnesses; and (4) all other practical problems that make a trial easy, expeditious and inexpensive.” 551 F.3d at 1319 (citing Piper Aircraft Co. v. Reyno, 454 U.S. 235, 241 n. 6, 102 S.Ct. 252, 70 L.Ed.2d 419 (1981)). The public interest factors include “(1) the administrative difficulties flowing from court congestion; (2) the local interest in having localized interests decided at home; (3) the familiarity of the forum with the law that will govern the case; and (4) the avoidance of unnecessary problems of conflicts of laws [or in] the application of foreign law.” TS Tech, 551 F.3d at 1319 (quoting Volkswagen, 545 F.3d at 315) (internal quotation marks omitted).

B. Application of the Factors

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hoffman v. Blaski
363 U.S. 335 (Supreme Court, 1960)
Van Dusen v. Barrack
376 U.S. 612 (Supreme Court, 1964)
Allied Chemical Corp. v. Daiflon, Inc.
449 U.S. 33 (Supreme Court, 1980)
Piper Aircraft Co. v. Reyno
454 U.S. 235 (Supreme Court, 1982)
Stewart Organization, Inc. v. Ricoh Corp.
487 U.S. 22 (Supreme Court, 1988)
In Re TS Tech USA Corp.
551 F.3d 1315 (Federal Circuit, 2008)
In Re Cordis Corporation
769 F.2d 733 (Federal Circuit, 1985)
In Re Calmar, Inc.
854 F.2d 461 (Federal Circuit, 1988)
Ricoh Co., Ltd. v. Honeywell, Inc.
817 F. Supp. 473 (D. New Jersey, 1993)
Cento Group, S.P.A. v. OroAmerica, Inc.
822 F. Supp. 1058 (S.D. New York, 1993)
Sanofi-Aventis Deutschland GmbH v. Genentech, Inc.
607 F. Supp. 2d 769 (E.D. Texas, 2009)
Murray v. Scott
176 F. Supp. 2d 1249 (M.D. Alabama, 2001)
Neil Bros. Ltd. v. World Wide Lines, Inc.
425 F. Supp. 2d 325 (E.D. New York, 2006)
In re Volkswagen of America, Inc.
545 F.3d 304 (Fifth Circuit, 2008)
Gates Learjet Corp. v. Jensen
743 F.2d 1325 (Ninth Circuit, 1984)

Cite This Page — Counsel Stack

Bluebook (online)
566 F.3d 1338, 91 U.S.P.Q. 2d (BNA) 1027, 2009 U.S. App. LEXIS 10882, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-genentech-inc-cafc-2009.